Top Tweets for #Metablok

over 4 years ago

Congratulations to @archbiopartners on the Phase III approval from Health Canada for #metablok / #Lsalt ! $Arch.v $achff @CATCOtrial

0

3

0

over 4 years ago

Huge news out on $Arch.v , with yet another third party publication on #metablok #Lsalt . One must remember that although in fully funded phase III @CATCOtrial , @archbiopartners is an organ inflammation trial, with a 20 billion unmet kidney market.

Maiwand_Walter's tweet photo. Huge news out on $Arch.v , with yet another third party publication on #metablok #Lsalt . One must remember that although in fully funded phase III @CATCOtrial , @archbiopartners is an organ inflammation trial, with a 20 billion unmet kidney market. https://t.co/Cq2sKrbcgY

1

5

2

0

over 4 years ago

@chamath @archbiopartners has a novel therapeutic #Lsaltpeptide #Metablok that is moving from Phase II to a Phase III which had the strongest animal data in the Kidney. $Arch.v With a current market cap of 200 million, I would do some DD here

0

2

1

0

over 4 years ago

With a signal from the recent Phase II results, It is very exciting to review historic (Now proven) Mechanism of Action material from Dipeptidase-1 ( #Metablok / #Lsalt ). Exciting future ahead for @archbiopartners in the #Lung #Liver & #Kidney #NovelTherapeutic $Arch.v $Achff

Hayt899's tweet photo. With a signal from the recent Phase II results, It is very exciting to review historic (Now proven) Mechanism of Action material from Dipeptidase-1 ( #Metablok / #Lsalt ). Exciting future ahead for @archbiopartners in the #Lung #Liver & #Kidney #NovelTherapeutic

$Arch.v $Achff https://t.co/HVmV1XtYBT

0

6

1

0

almost 5 years ago

@atrembla @jkenney @calgaryherald I am hopeful that the @CATCOtrial can have #Metablok first dose in the short term to help in this next wave. Do you think there is potential for a reduction in hospitalization days? $Arch.v

0

3

1

0

almost 5 years ago

“This variant did surprise us — it has a big jump in evolution, many more mutations than we expected, especially after a very severe third wave of Delta,” Professor de Oliveira said. $Arch.v #Metablok #Lsalt

0

4

0

almost 5 years ago

With @archbiopartners Phase II trial currently having Data reviewed by a third party, the stock is currently trading at 182 mil (US) market cap with the potential to treat a 20 billion/year unmet market. #LSALT #Metablok #Lung #Liver #Kidney #inflammation $Arch.v #StocksToBuy

0

4

1

0

about 5 years ago

@archbiopartners third party data analysis expected to occur during the latter part of July #Metablok #Lsalt . Potential progress in therapeutics for #inflammation , Phase II results could be a game changer in the #Lung #Liver #Kidney #COVID19 . $Arch.v $Achff

0

3

0

over 5 years ago

Arch Biopartners $ARCH.V announced today – it has completed enrollment for its Phase II study of #Metablok (LSALT Peptide), targeting acute lung injury and acute kidney injury (#AKI) caused by #inflammation in patients with severe cases of #COVID19. https://t.co/Gau7Jx0bD1

0

8

2

0

over 5 years ago

Arch Biopartners - $ARCH.V announced today that the ongoing international #Phase2 trials of #Metablok (LSALT Peptide), are approved to expand in Turkey, to treat patients currently hospitalized with severe cases of #COVID19 - Full Release here: https://t.co/Bmzl5k68XJ

0

6

0

over 5 years ago

Arch Biopartners announced today that it has received Health Canada authorization to amend the Phase II Trial Protocol for LSALT Peptide #Metablok $ARCH.V Full Release: https://t.co/hcO1tns71x

0

3

0

over 5 years ago

Arch Biopartners has announced that the Peter Lougheed Centre, in Calgary, is the second hospital in Canada to join the international #Phase2 trial of #Metablok (LSALT Peptide) - $ARCH.V lead candidate to treat patients hospitalized with #COVID19. https://t.co/SD6FYCsAIu

0

4

1

0

Thesis Capital Inc.

@ThesisCap

over 5 years ago

Our favourite #inflammation company was featured in the @calgaryherald today. The article discusses $ARCH.V current #phase2 of their leading drug candidate #metablok #biotech #biotechstocks

over 5 years ago

@calgaryherald feature with @archbiopartners CSO Dr. Dan Muruve and Dr. Alain Tremblay by @jasonfherring - Reporting on current activities in Calgary in our ongoing #Phase2 trial of #metablok, $ARCH.V lead drug candidate to treat #COVID19 patients. https://t.co/mRrgTVOH7F

0

2

0

2

0

over 5 years ago

@calgaryherald feature with @archbiopartners CSO Dr. Dan Muruve and Dr. Alain Tremblay by @jasonfherring - Reporting on current activities in Calgary in our ongoing #Phase2 trial of #metablok, $ARCH.V lead drug candidate to treat #COVID19 patients. https://t.co/mRrgTVOH7F

0

2

0

over 5 years ago

@archbiopartners CSO quoted in an interview “Early data on the drug is positive”. This early indication is beyond exciting for a NEW Canadian Mechanism of Action #covid19 #metablok #Lsalt #inflammation #lung #liver #kidney #humantrials $Arch.v https://t.co/oA4lLakoDs

1

4

1

0

over 5 years ago

$ARCH.V - has received approval in #Turkey to expand the ongoing international #Phase2 trial to include additional patients. The #Metablok trial, targets acute organ injury caused by #inflammation, with hospitalized patients with severe cases of #COVID19 https://t.co/81ySHxGPqk

0

3

0

over 5 years ago

@archbiopartners receives ethics committee approval in Turkey to dose additional patients in the phase II trial for #LSALT Peptide. #Metablok #Inflammation #Lung #liver #Kidney #Phase2 $Arch.v

0

2

0